ClinicalTrials.gg
CompletedNCT02138916GALATHEAUpdated Jun 13, 2019Results posted

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

A Phase 3 interventional study of Benralizumab Arm A and Benralizumab Arm B in Moderate to Very Severe Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 409 sites in 17 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-13.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung Diseases, ObstructiveReclassifiedWhy we changed it
Registry
Lung Diseases, Obstructive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases, Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,656
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
16th of 194
1,656 · median 137
Started
2014
with 13 others
Phase 3
76 of 284
4 open now
Registered
146th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 16th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 76 in phase 3, and was the 146th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies

03

Conditions studied

  • Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Keywords

  • Obstructive Lung Diseases
  • Chronic Obstructive Pulmonary Disease
  • Lung Disease
  • Bronchial Diseases
  • COPD Exacerbation
  • Respiratory Tract Diseases
04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's enrollment of 1,656 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:1.. 2.Subjects 40-85 y.o. 3.Moderate to very severe with Post Bronchodilator (BD) >20% and ≤65%. 4.≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization within 2-52 weeks prior to Visit1. 5. Modified Medical Research Council (mMRC) score ≥1 at Visit 1. 6.Treatment with double or triple therapy throughout the year prior to Visit 1, constant 2 weeks prior to Visit 1. 7.Tobacco history of ≥10 pack-years. 8.Women of must use a highly effective form of from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result at Visit 1. 9.Male subjects who are sexually active must be surgically sterile one year prior to Visit 1 or use an adequate method of contraception from the first Product (IP) dose until 16 weeks after their last dose. 10.Compliance with maintenance therapy during run-in ≥70%. 11. Blood eosinophils due to subject's stratification and cap for blood eosinophil levels.When any eosinophil cohort is full, subjects in the completed cohort will not be randomised and will be withdrawn from the study. Exclusion criteria: 1. pulmonary disease other than COPD or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.

  1. Any disorder or major physical impairment that is not stable by Investigator opinion and/or could affect: - subject safety-study findings or their interpretation or subject's ability to complete the entire study duration.
  1. Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant cardiovascular disorder that in Investigator's judgment may put the patient at risk or negatively affect the study outcome.
  1. Treatment with systemic and/or antibiotics, and/or hospitalization for a COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in period.
  1. Acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 2 weeks prior to Visit1or during the enrolment and run-in period.
  1. Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.
  1. Pregnant, breastfeeding, or lactating women. 8. Risk factors for pneumonia 9. History of anaphylaxis to any other biologic therapy. 10. Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right ventricular failure.
  1. Use of medication within 2 weeks prior to Visit1 and/or during the enrolment and run-in period.
  1. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1.
  1. Evidence of active tuberculosis (TB) without an appropriate course of treatment.
  1. Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
  1. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
  1. Previous treatment with benralizumab. 17. Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,656 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm A

    Benralizumab administered subcutaneously

    Drug: Benralizumab Arm A

  • Experimental
    Benralizumab Arm B

    Benralizumab administered subcutaneously

    Drug: Benralizumab Arm B

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Drug: Placebo

Interventions

  • DrugBenralizumab Arm A

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • DrugBenralizumab Arm B

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • DrugPlacebo

    Placebo subcutaneously on study week 0 until study week 48 inclusive

07

What researchers measure

Primary outcomes

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: From first IP to week 56

Secondary outcomes

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL

    A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: From first IP to week 56

  2. Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL

    Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.

    Time frame: First IP up to end of treatment Week 56

  3. Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL

    SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.

    Time frame: First IP up to Week 56

  4. Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL

    CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.

    Time frame: First IP up to Week 56

  5. Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL

    The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.

    Time frame: First IP up to Week 56

  6. Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL

    The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.

    Time frame: First IP up to Week 56

  7. Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL

    Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.

    Time frame: First IP up to Week 56

  8. Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.

    Time frame: Immediately following first IP up to week 56

  9. Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.

    Time frame: Immediately following first IP up to week 56

  10. Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.

    Time frame: Immediately following first IP up to week 56

  11. Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following first IP up to week 56

  12. Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL

    A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.

    Time frame: Immediately following first IP up to week 56

  13. Time to First COPD Exacerbation

    Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation

    Time frame: Immediately following first IP up to week 56

  14. Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following first IP up to week 56

  15. Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL

    Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.

    Time frame: Immediately following first IP up to week 56

  16. Duration of Study Treatment Administration

    Duration of study treatment is calculated from first dose date to last dose date + 1 day.

    Time frame: From first dose date to last dose date, 48 weeks per protocol.

  17. Serum Concentration of Benralizumab

    PK serum samples were collected pre-dose at each visit.

    Time frame: Pre-first dose and pre-dose at end of treatment (week 56)

  18. Immunogenicity of Benralizumab

    Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented

    Time frame: Pre-treatment until end of follow-up, week 60 per protocol.

08

Results

Posted Jun 13, 2019

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab 30 mgBenralizumab 100 mgPlacebo
Started554552550
Completed497492491
Not completed576059
Withdrew: Eg., meds change, lack of efficacy, etc.697
Withdrew: Death141112
Withdrew: Withdrawal by subject273132
Withdrew: Study specific withdrawal criteria001
Withdrew: Incorrect enrolment110
Withdrew: Severe non-compliance121
Withdrew: Lost to follow-up423
Withdrew: Adverse event443

Outcome measures

PrimaryAnnual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
From first IP to week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL1.19 (1.04 to 1.36)1.03 (0.9 to 1.19)1.24 (1.08 to 1.42)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.6490 · Rate ratio: 0.96 · 95% CI 0.8 to 1.15Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.0525 · Risk ratio (rr): 0.83 · 95% CI 0.69 to 1.00Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
SecondaryAnnual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL

A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
From first IP to week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL
Exacerbations per yearBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL1.4 (1.19 to 1.64)1.32 (1.12 to 1.56)1.30 (1.11 to 1.52)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.5236 · Risk ratio (rr): 1.07 · 95% CI 0.86 to 1.34Model includes treatment group, region, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.8812 · Risk ratio (rr): 1.02 · 95% CI 0.82 to 1.27Model includes treatment group, EOS cohort, region, number of exacerbations in the previous year.
SecondaryMean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL

Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.

Time frame:
First IP up to end of treatment Week 56
Reported as:
Mean · Liter
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL
LiterBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL0.014 ± 0.2820.031 ± 0.2940.010 ± 0.275
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.7550 · Mean difference (final values): 0.007 · 95% CI -0.035 to 0.048Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.3285 · Mean difference (final values): 0.021 · 95% CI -0.021 to 0.062Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL

SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.

Time frame:
First IP up to Week 56
Reported as:
Mean · Percentage
Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL
PercentageBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL-5.025 ± 14.677-6.723 ± 15.723-3.913 ± 15.039
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.2906 · Mean difference (final values): -1.011 · 95% CI -2.887 to 0.865Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0264 · Mean difference (final values): -2.136 · 95% CI -4.020 to -0.251Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL

CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.

Time frame:
First IP up to Week 56
Reported as:
Mean · Score on a scale
Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL-1.50 ± 6.89-2.43 ± 6.34-1.22 ± 6.53
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.6782 · Mean difference (final values): -0.19 · 95% CI -1.08 to 0.70Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0753 · Mean difference (final values): -0.81 · 95% CI -1.70 to 0.08Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL

The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.

Time frame:
First IP up to Week 56
Reported as:
Mean · Score on a scale
Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL-1.085 ± 5.273-1.354 ± 5.599-0.504 ± 5.674
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0889 · Mean difference (final values): -0.585 · 95% CI -1.260 to 0.089Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0413 · Mean difference (final values): -0.703 · 95% CI -1.378 to -0.028Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL

The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.

Time frame:
First IP up to Week 56
Reported as:
Mean · Puffs/day
Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL
Puffs/dayBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL-0.05 ± 3.21-0.27 ± 2.710.29 ± 3.03
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0728 · Mean difference (final values): -0.348 · 95% CI -0.728 to 0.032Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0121 · Mean difference (final values): -0.487 · 95% CI -0.868 to -0.107Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL

Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.

Time frame:
First IP up to Week 56
Reported as:
Mean · Proportion of nights
Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL
Proportion of nightsBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL-0.088 ± 0.310-0085 ± 0.283-0.049 ± 0.307
Statistical analysis
  • Benralizumab 30 mg · Mixed Models Analysis · p = 0.0235 · Mean difference (final values): -0.041 · 95% CI -0.077 to -0.006Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg · Mixed Models Analysis · p = 0.0158 · Mean difference (final values): -0.044 · 95% CI -0.080 to -0.008Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryNumber of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.

Time frame:
Immediately following first IP up to week 56
Reported as:
Count of participants · Participants
Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL
ParticipantsBenralizumab 30 mgBenralizumab 100 mgPlacebo
0180184179
110110399
2424934
3251415
4171314
5565
6442
7615
8114
9121
10010
SecondarySeverity of EXACT-PRO for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.

Time frame:
Immediately following first IP up to week 56
Reported as:
Mean · Score on a scale
Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 30 mgBenralizumab 100 mgPlacebo
Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL51.5 ± 11.3050.8 ± 10.7052.0 ± 11.20
SecondaryDuration of EXACT-PRO for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.

Time frame:
Immediately following first IP up to week 56
Reported as:
Mean · Days
Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL
DaysBenralizumab 30 mgBenralizumab 100 mgPlacebo
Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL82.2 ± 95.8088.3 ± 105.30101.7 ± 113.70
SecondaryAnnual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following first IP up to week 56
Reported as:
Least squares mean · Exacerbations per year
Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL1.14 (0.98 to 1.31)1.02 (0.88 to 1.19)1.04 (0.90 to 1.21)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.4080 · Rate ratio: 1.09 · 95% CI 0.89 to 1.34Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.8688 · Rate ratio: 0.98 · 95% CI 0.80 to 1.21Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
SecondaryNumber of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL

A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.

Time frame:
Immediately following first IP up to week 56
Reported as:
Count of participants · Participants
Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL
ParticipantsBenralizumab 30 mgBenralizumab 100 mgPlacebo
Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL204203198
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4850 · Odds ratio (or): 0.90 · 95% CI 0.66 to 1.22CMH test controlling for EOS cohort, region, and background therapy.
  • Benralizumab 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4489 · Odds ratio (or): 0.89 · 95% CI 0.65 to 1.21CMH test controlling for EOS cohort, region, and background therapy.
SecondaryTime to First COPD Exacerbation

Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation

Time frame:
Immediately following first IP up to week 56
Reported as:
Median · Days
Time to First COPD Exacerbation
DaysBenralizumab 30 mgBenralizumab 100 mgPlacebo
Time to First COPD Exacerbation333 (273 to 400)329 (262 to 396)337 (261 to 390)
SecondaryAnnual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following first IP up to week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL0.27 (0.20 to 0.35)0.15 (0.11 to 0.20)0.25 (0.19 to 0.33)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.7733 · Rate ratio: 1.06 · 95% CI 0.73 to 1.53Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).
  • Benralizumab 100 mg vs Placebo · Nagative binomial · p = 0.0114 · Rate ratio: 0.58 · 95% CI 0.39 to 0.89Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).
SecondaryNumber of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL

Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.

Time frame:
Immediately following first IP up to week 56
Reported as:
Count of participants · Participants
Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL
ParticipantsBenralizumab 30 mgBenralizumab 100 mgPlacebo
Hospitalisations603850
Emergency Department Visits363543
Unscheduled Outpatient Visits219236202
Home Visits182218
Telephone calls110111104
Ambulance transports161220
SecondaryDuration of Study Treatment Administration

Duration of study treatment is calculated from first dose date to last dose date + 1 day.

Time frame:
From first dose date to last dose date, 48 weeks per protocol.
Reported as:
Mean · Days
Duration of Study Treatment Administration
DaysBenralizumab 30 mgBenralizumab 100 mgPlacebo
Duration of Study Treatment Administration302.4 ± 85.73304.0 ± 82.40302.5 ± 88.47
SecondarySerum Concentration of Benralizumab

PK serum samples were collected pre-dose at each visit.

Time frame:
Pre-first dose and pre-dose at end of treatment (week 56)
Reported as:
Geometric mean · ng/mL
Serum Concentration of Benralizumab
ng/mLBenralizumab 30 mgBenralizumab 100 mg
BaselineNA ± NANA ± NA
Week 56219.45 ± 233.21699.89 ± 243.20
SecondaryImmunogenicity of Benralizumab

Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented

Time frame:
Pre-treatment until end of follow-up, week 60 per protocol.
Reported as:
Count of participants · Participants
Immunogenicity of Benralizumab
ParticipantsBenralizumab 30 mgBenralizumab 100 mgPlacebo
ADA prevalence536439
ADA incidence444724
Both base/post-baseline positive5717
Only post baseline positive434620
Only baseline positive5112
ADA persistently positive283414
ADA transiently positive15126
nAb prevalence434325
nAb incidence413718

Adverse events

Collected over From the time the patient signed informed consent through the treatment period up to the follow-up visit (week 60).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30 mg15/554 (2.7%)151/554 (27.3%)293/554 (52.9%)
Benralizumab 100 mg11/552 (2%)177/552 (32.1%)318/552 (57.6%)
Placebo13/550 (2.4%)176/550 (32%)282/550 (51.3%)
Most frequent serious events
Showing 10 of 244
Most frequent serious events
EventBenralizumab 30 mgBenralizumab 100 mgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders97/55478/552100/550
PneumoniaInfections and infestations22/55418/55216/550
Pneumonia bacterialInfections and infestations5/5548/55210/550
Atrial fibrillationCardiac disorders4/5548/5522/550
PneumothoraxRespiratory, thoracic and mediastinal disorders2/5541/5525/550
Acute myocardial infarctionCardiac disorders2/5541/5524/550
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/5541/5524/550
Myocardial infarctionCardiac disorders4/5543/5521/550
Coronary artery stenosisCardiac disorders0/5540/5523/550
BronchitisInfections and infestations1/5543/5523/550
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBenralizumab 30 mgBenralizumab 100 mgPlacebo
Viral upper respiratory tract infectionInfections and infestations83/55495/55266/550
BronchitisInfections and infestations59/55484/55280/550
Upper respiratory tract infectionInfections and infestations69/55474/55265/550
Lower respiratory tract infectionInfections and infestations50/55432/55229/550
Oedema peripheralGeneral disorders11/55426/55211/550
HeadacheNervous system disorders21/55426/55220/550
Back painMusculoskeletal and connective tissue disorders21/55425/55219/550
DyspnoeaRespiratory, thoracic and mediastinal disorders24/55417/55223/550
Urinary tract infectionInfections and infestations23/55422/55215/550
CoughRespiratory, thoracic and mediastinal disorders16/55414/55221/550

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Benralizumab 30 mgBenralizumab 100 mgPlaceboTotal
Mean65.9 ± 7.7765.3 ± 8.0565.2 ± 8.2265.5 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mgBenralizumab 100 mgPlaceboTotal
Female172180175527
Male3823723751129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 30 mgBenralizumab 100 mgPlaceboTotal
White4964934881477
Black or African American4111025
Asian484646140
Other62614
09

Study locations

409 sites
  • Research Site
    Andalusia, Alabama 36420, United States
  • Research Site
    Birmingham, Alabama 35243, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Dothan, Alabama 36305, United States
  • Research Site
    Jasper, Alabama 35501, United States
  • Research Site
    Little Rock, Arkansas 72209, United States
  • Research Site
    Beverly Hills, California 90212, United States
  • Research Site
    Gold River, California 95670, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Huntington Park, California 90255-6046, United States
  • Research Site
    Lakewood, California 90805, United States
  • Research Site
    Lomita, California 90717, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Palm Desert, California 92260, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Riverside, California 92506, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    Santa Ana, California 92704, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    New Haven, Connecticut 06520-8057, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Fort Lauderdale, Florida 33316, United States
  • Research Site
    Gainesville, Florida 32608, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Kissimmee, Florida 34741, United States
  • Research Site
    Loxahatchee Groves, Florida 33470, United States
  • Research Site
    Miami Springs, Florida 33166, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Orlando, Florida 32803, United States
  • Research Site
    Orlando, Florida 32819, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Panama City, Florida 32405, United States
  • Research Site
    Port Orange, Florida 32129, United States
  • Research Site
    Saint Petersburg, Florida 33707, United States
  • Research Site
    Saint Petersburg, Florida 33713, United States
  • Research Site
    Sebring, Florida 33870, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Winter Park, Florida 32789-4681, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Calhoun, Georgia 30701, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    Duluth, Georgia 30096, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Eagle, Idaho 83616, United States
  • Research Site
    Aurora, Illinois 60506, United States
  • Research Site
    Chicago, Illinois 60602, United States
  • Research Site
    Evanston, Illinois 60201, United States
  • Research Site
    Michigan City, Indiana 46360, United States
  • Research Site
    Valparaiso, Indiana 46383, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Fort Mitchell, Kentucky 41017, United States
  • Research Site
    Hazard, Kentucky 41701, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Rochester, Michigan 48307, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Saint Charles, Missouri 63301, United States
  • Research Site
    Saint Louis, Missouri 63143, United States
  • Research Site
    Las Vegas, Nevada 89123, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Albuquerque, New Mexico 87108, United States
  • Research Site
    Bronxville, New York 10708, United States
  • Research Site
    Brooklyn, New York 11229, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    Fayetteville, New York 13066, United States
  • Research Site
    New York, New York 10022, United States
  • Research Site
    New York, New York 10036, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Elizabeth City, North Carolina 27909, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Greensboro, North Carolina 27401, United States
  • Research Site
    Mount Airy, North Carolina 27030, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Dayton, Ohio 45459, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Bend, Oregon 97701, United States
  • Research Site
    Medford, Oregon 97504, United States

Showing the first 100 of 409 sites across 17 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, Makulova N, Shih VH, Brooks L, Barker P, Martin UJ, Newbold P. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020 Feb;8(2):158-170. doi: 10.1016/S2213-2600(19)30338-8. Epub 2019 Sep 28. PubMed 31575508 ↗
  • Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramirez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. PubMed 31112385 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Apr 2018, 45 months.

Results were first posted in Jun 2019, 1 year 2 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 45 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
May 15, 2014
StartActual
Jun 13, 2014
Primary completionActual
Apr 10, 2018
CompletionActual
Apr 10, 2018
Results first posted
Jun 13, 2019
Last update
Jun 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02138916
Lead sponsor
AstraZeneca
Collaborators
MedImmune LLC
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Jun 13, 2014
Primary completion
Apr 10, 2018
Completion
Apr 10, 2018
Results posted
Jun 13, 2019
Last update
Jun 13, 2019

Study contacts

Gerard Criner, MD
principal investigator · Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion